Expert Patient Capacity Building Update
Canadians with NMD, their families, and advocates are increasingly asked to take an active role in research initiatives. Research and advocacy training empowers patients and ensures they have the confidence and knowledge needed to share their expertise to guide discussions and inform decisions regarding health care, research, and therapy development for policy makers, industry, and scientists.
The NMD4C is involved in several activities under the provision of our Training and Education initiatives, including the establishment of expert patient capacity building (EPCB) resources for Canadian NMD patients. The EPCB team’s work involves the promotion of patient engagement in all aspects of NMD, and the development of easy-to-use and accessible Canadian NMD training modules and resources for both patients and researchers to support patient-oriented neuromuscular research in Canada.
To facilitate the network’s EPCB activities, the NMD4C is excited to announce the hiring of Patricia Mortenson, who has joined this team as project coordinator.
Read Patricia’s full bio here!
To assist in the development of modules to train patients and researchers to partner effectively, the EPCB team is reviewing the Canadian research landscape to find current resources and programs. Throughout all EPCB work, the team will utilize the Strategy for Patient-Oriented Research (SPOR) Patient Engagement Framework developed by CIHR. This framework allows patients to provide knowledge and input drawn from their unique experience gained through living with a condition or illness, and their first-hand experience in navigating treatments and the Canadian health care system.
The NMD4C encourages you to share any relevant expert patient capacity building resources that you know of with our team!
If you are a researcher who has experience in working with expert patients, we would also love to hear from you!
Please complete this short 5-minute survey here!
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.